Lambert-Eaton Syndrome

  • C. Michel Harper
  • Vanda A. Lennon
Part of the Current Clinical Neurology book series (CCNEU)


The Lambert-Eaton syndrome (LES) is an autoimmune presynaptic disorder of peripheral cholinergic neurotransmission characterized by proximal weakness and autonomic dysfunction. Approximately 60% of cases are associated with small-cell lung carcinoma (SCLC), which can appear before or after the clinical manifestations of LES. The P-/Q-type voltage-gated calcium channel in motor nerve terminals, classified by structure and function as Cav2.1, is the presumptive target of antibodies that cause LES. Antigenically similar calcium channels are expressed in the surface membranes of SCLC tumor cells. When neuronal Cav2.1 channels are functionally impaired, nerve-stimulated quantal release of the neurotransmitter acetylcholine (ACh) is reduced. This lowers the safety margin for synaptic transmission at the neuromuscular junction and in certain autonomic nerve terminals, leading to weakness at rest that is temporarily improved by exertion, as well as xerostomia, impotence, and hypohidrosis. The diagnosis of LES is based on clinical manifestations, abnormalities on nerve conduction studies and EMG, and serological testing. Weakness predominately affects hip flexor muscles but can be generalized. Nerve conduction studies classically demonstrate low-amplitude compound muscle action potentials at rest with facilitation induced by exercise or by high-frequency repetitive stimulation. Needle EMG testing typically demonstrates small varying motor unit potentials without fibrillations. P-/Q-type voltage-gated calcium channel antibodies are detected in serum in more than 90% of LES patients. Treatment of weakness is symptomatic, with agents that improve the safety margin of neuromuscular transmission (e.g., 3,4-diaminopyridine in combination with pyridostigmine) and immunosuppressant therapy, and is cancer-directed in paraneoplastic cases.


Paraneoplastic syndrome Small-cell lung cancer P-/Q-type voltage-gated calcium channels (Cav2.1) Autoimmune neuromuscular disease 3,4-diaminopyridine Dysautonomia 


  1. 1.
    Anderson HJ, Churchill-Davidson HC, Richardson AT. Bronchial neoplasm with myasthenia; prolonged apnoea after administration of succinylcholine. Lancet. 1953;265(6799):1291–3.PubMedCrossRefGoogle Scholar
  2. 2.
    Griesmann GE, Harper CM, Lennon VA. Paraneoplastic myasthenia gravis and lung carcinoma: distinction from Lambert-Eaton myasthenic syndrome and hypothesis of aberrant muscle acetylcholine receptor expression. Muscle Nerve. 1998;7(Suppl 7):S122.Google Scholar
  3. 3.
    Lambert EH, Eaton LM, Rooke ED. Defect of neuromuscular transmission associated with malignant neoplasm. Am J Phys. 1956;187:612.Google Scholar
  4. 4.
    Eaton LM, Lambert EH. Electromyography and electrical stimulation of nerves in diseases of the motor unit: observations on myasthenic syndrome associated with malignant tumors. JAMA. 1957;163:1117–24.CrossRefGoogle Scholar
  5. 5.
    Lambert EH, Rooke ED, Eaton LM, Hodgson CH. Myasthenic syndrome occasionally associated with bronchial neoplasm. In: Thomas CC, editor. Myasthenia gravis; 1959. p. 362.Google Scholar
  6. 6.
    Lambert EH, Rooke ED, Eaton LM, Hodgson CH. Myasthenic syndrome occasionally associated with bronchial neoplasm: neurophysiologic studies. In: Viets HR, editor. Myasthenia gravis. Springfield: Charles C. Thomas; 1961. p. 362–410.Google Scholar
  7. 7.
    Lambert EH, Rooke ED. Myasthenic state and lung cancer. In: Brain WR, Norris FH, editors. The remote effects of cancer on the nervous system (contemporary neurology symposia), vol. 1. New York: Grune & Stratton; 1965. p. 67–80.Google Scholar
  8. 8.
    Elmqvist D, Lambert EH. Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma. Mayo Clin Proc. 1968;43:689–713.PubMedGoogle Scholar
  9. 9.
    Lambert EH, Elmqvist D. Quantal components of end-plate potentials in the myasthenic syndrome. Ann N Y Acad Sci. 1971;183:183–99.PubMedCrossRefGoogle Scholar
  10. 10.
    Gutmann L, Crosby TW, Takamori M, Martin JD. The Eaton-Lambert syndrome and autoimmune disorders. Am J Med. 1972;53:354–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Lennon VA, Lambert EH, Whittingham S, Fairbanks V. Autoimmunity in the Lambert-Eaton myasthenic syndrome. Muscle Nerve. 1982;5:S21–5.PubMedGoogle Scholar
  12. 12.
    Fukunaga H, Engel AG, Osame M, Lambert EH. Paucity and disorganization of presynaptic membrane active zones in the Lambert-Eaton myasthenic syndrome. Muscle Nerve. 1982;5:686–97.CrossRefGoogle Scholar
  13. 13.
    Engel AG. Anatomy and molecular architecture of the neuromuscular junction. In: Engel AG, editor. Myasthenia gravis and myasthenic syndromes. New York: Oxford Press; 1999. p. 3–40.Google Scholar
  14. 14.
    Lang B, Newsom-Davis J, Wray D, Vincent A, Murray N. Autoimmune etiology for myasthenic (Eaton-Lambert) syndrome. Lancet. 1981;2:224–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Kim YI. Passively transferred Lambert-Eaton syndrome in mice receiving purified IgG. Muscle Nerve. 1986;9:523–30.PubMedCrossRefGoogle Scholar
  16. 16.
    Fukunaga H, Engel AG, Lang B, Newsom-Davis J, Vincent A. Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci U S A. 1983;80:7636–40.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Lambert EH, Lennon VA. Selected IgG rapidly induces Lambert-Eaton myasthenic syndrome in mice: complement independence and EMG abnormalities. Muscle Nerve. 1988;11:1133–45.PubMedCrossRefGoogle Scholar
  18. 18.
    Roberts A, Perera S, Lang B, Vincent A, Newsom-Davis J. Paraneoplastic myasthenic syndrome IgG inhibits 45Ca flux in human small cell carcinoma line. Nature. 1985;317:737–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Lennon VA, Lambert EH. Autoantibodies bind solubilized calcium channel-omega-conotoxin complexes from small cell lung carcinoma: a diagnostic aid for Lambert-Eaton myasthenic syndrome. Mayo Clin Proc. 1989;64:1498–504.PubMedCrossRefGoogle Scholar
  20. 20.
    Sher E, Canal N, Piccolo G, Gotti C, Scoppetta C, Evoli A, Clementi F. Specificity of calcium channel autoantibodies in Lambert-Eaton myasthenic syndrome. Lancet. 1989;ii:640–3.CrossRefGoogle Scholar
  21. 21.
    Leys K, Lang B, Johnston I, Newsom-Davis J. Calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Ann Neurol. 1991;29:307–14.PubMedCrossRefGoogle Scholar
  22. 22.
    Lennon VA, Kryzer TJ, Griesmann GE, O'Suilleabhain PE, Windebank AJ, Woppmann A, Miljanich GP, Lambert EH. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995;332:1467–71.PubMedCrossRefGoogle Scholar
  23. 23.
    Lennon VA. Serologic profile of myasthenia gravis and distinction from Lambert-Eaton myasthenic syndrome. Neurology. 1997;48(Suppl 5):S23–7.CrossRefGoogle Scholar
  24. 24.
    Chalk CH, Murray NM, Newsom-Davis J, O'Neill JH, Spiro SG. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology. 1990;40:1552–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Streib EW, Rothner AD. Lambert-Eaton myasthenic syndrome: long-term treatment of three patients with prednisone. Ann Neurol. 1981;10:448–53.PubMedCrossRefGoogle Scholar
  26. 26.
    Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology. 1984;34:480–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Lundh H, Nilsson O, Rosen I. Current therapy of the Lambert-Eaton myasthenic syndrome. Prog Brain Res. 1990;84:163–70.PubMedCrossRefGoogle Scholar
  28. 28.
    Maddison P, Lang B, Mills K, Newsom-Davis J. Long-term outcome in Lambert-Eaton myasthenic syndrome without lung cancer. J Neurol Neurosurg Psychiatry. 2001;70:212–7.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Lundh H, Nilsson O, Rosen I. Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine. Neurology. 1984;34:1324–30.PubMedCrossRefGoogle Scholar
  30. 30.
    McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med. 1989;321:1567–71.PubMedCrossRefGoogle Scholar
  31. 31.
    Oh SJ, Kim DS, Head TC, Claussen GC. Low dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome. Muscle Nerve. 1997;20:1146–52.PubMedCrossRefGoogle Scholar
  32. 32.
    Boonyapisit K, Kaminski HJ, Ruff RL. The molecular basis of neuromuscular transmission disorders. Am J Med. 1999;106:97–113.PubMedCrossRefGoogle Scholar
  33. 33.
    Lambert EH, Okihiro M, Rooke ED. Clinical physiology of the neuromuscular junction. In: Paul WM, Daniel EE, Kay CM, Monckton G, editors. Muscle. Oxford: Pergamon Press; 1965. p. 487–97.Google Scholar
  34. 34.
    Hughes BW, Kusner LL, Kaminski HJ. Molecular architecture of the neuromuscular junction. Muscle Nerve. 2006;33:445–61.PubMedCrossRefGoogle Scholar
  35. 35.
    Anderson CR, Stevens CF. Voltage clamp analysis of acetylcholine produced end-plate current fluctuation at frog neuromuscular junction. J Physiol. 1973;235:655–91.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Jablecki CK. Electrodiagnostic evaluation of patients with myasthenia gravis and related disorders. Neurol Clin. 1985;3:557–72.PubMedGoogle Scholar
  37. 37.
    Jones SW. Overview of voltage-dependent calcium channels. J Bioenerg Biomembr. 1998;30:299–312.PubMedCrossRefGoogle Scholar
  38. 38.
    Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment. Neurology. 2000;54:2176–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Slater CR. The functional organization of motor nerve terminals. Prog Neurobiol. 2015;134:55–103.PubMedCrossRefGoogle Scholar
  40. 40.
    Sudhof TC. The synaptic vesicle cycle. Annu Rev Neurosci. 2004;27:509–47.PubMedCrossRefGoogle Scholar
  41. 41.
    Striegel AR, Biela LM, Evans CS, Wang Z, Delehoy JB, Sutton RB, et al. Calcium binding by synaptotagmin’s C2A domain is an essential element of the electrostatic switch that triggers synchronous synaptic transmission. J Neurosci. 2012;32:1253–60.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Takamura M. Structure of the neuromuscular junction: function and cooperative mechanisms in the synapse. Ann N Y Acad Sci. 2012;1274:14–23.CrossRefGoogle Scholar
  43. 43.
    Black JL, Lennon VA. Identification and cloning of human neuronal high voltage-gated calcium channel γ-2 and γ-3 subunits: neurological implications. Mayo Clin Proc. 1999;74:357–61.PubMedCrossRefGoogle Scholar
  44. 44.
    Molenaar PC, Newsom-Davis J, Polak RL, Vincent A. Eaton-Lambert syndrome: acetylcholine and choline acetyltransferase in skeletal muscle. Neurology. 1982;32:1061–5.PubMedCrossRefGoogle Scholar
  45. 45.
    Simms BA, Zamponi GW. Neuronal voltage-gated calcium channels: structure, function, and dysfunction. Neuron. 2014;82:24–45.PubMedCrossRefGoogle Scholar
  46. 46.
    Harper CM. Electrodiagnosis of endplate disease. In: Engel AG, editor. Myasthenia gravis and myasthenic syndromes. New York: Oxford Press; 1999. p. 65–86.Google Scholar
  47. 47.
    Denys E, Lennon VA. Asymptomatic Lambert-Eaton syndrome. Muscle Nerve. 2014;49:764–7.PubMedCrossRefGoogle Scholar
  48. 48.
    O’Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain. 1988;111:577–96.PubMedCrossRefGoogle Scholar
  49. 49.
    Titulaer MJ, Lang B, Jan J, Verschuuren GM. Lambert–Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10:1098–107.PubMedCrossRefGoogle Scholar
  50. 50.
    O’Suilleabhain P, Low PA, Lennon VA. Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serological and clinical correlates. Neurology. 1998;50:88–93.PubMedCrossRefGoogle Scholar
  51. 51.
    Hillman D, Chen S, Aung TT, Cherksey B, Sugimori M, Llinás RR. Localization of P-type calcium channels in the central nervous system. Proc Natl Acad Sci U S A. 1991;88:7076–80.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Waterman SA, Lang B, Newsom-Davis J. Effect of Lambert-Eaton myasthenic syndrome antibodies on autonomic neurones in the mouse. Ann Neurol. 1997;42:147–56.PubMedCrossRefGoogle Scholar
  53. 53.
    Komai K, Jwasa K, Takamori M. Calcium channel peptide can cause an autoimmune-mediated model of Lambert-Eaton myasthenic syndrome in rats. J Neurol Sci. 1999;166:126–30.PubMedCrossRefGoogle Scholar
  54. 54.
    Oguro-Okano M, Griesmann GE, Wieben ED, Slaymaker S, Snutch TP, Lennon VA. Molecular diversity of neuronal type calcium channels identified in small cell lung carcinoma. Mayo Clin Proc. 1992;67:1150–9.PubMedCrossRefGoogle Scholar
  55. 55.
    De Aizpurua HJ, Lambert EH, Griesmann GE, Olivera BM, Lennon VA. Antagonism of voltage gated calcium channels in small cell carcinomas of patients with and without Lambert Eaton myasthenic syndrome by autoantibodies, ω conotoxin and adenosine. Cancer Res. 1988;48:4719–24.PubMedGoogle Scholar
  56. 56.
    Maddison P, Newsom-Davis J, Mills KR, Souhami RL. Favorable prognosis in Lambert- Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet. 1999;353:117–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Prior C, Lang B, Wray D, Newsom-Davis J. Action of Lambert-Eaton myasthenic syndrome IgG at mouse motor nerve terminals. Ann Neurol. 1985;17:587–92.PubMedCrossRefGoogle Scholar
  58. 58.
    Fukuoka T, Engel AG, Lang B, Newsom-Davis J, Prior C, Wray DW. Lambert-Eaton myasthenic syndrome: I. Early morphological effects of IgG on the presynaptic membrane active zones. Ann Neurol. 1987;22:193–9.PubMedCrossRefGoogle Scholar
  59. 59.
    Hajela RK, Huntoon KM, Atchison WD. Lambert-Eaton syndrome antibodies target multiple subunits of voltage-gated Ca2+ channels. Muscle Nerve. 2015;51:176–84.PubMedCrossRefGoogle Scholar
  60. 60.
    Lang B, Vincent A, Murray NM, Newsom-Davis J. Lambert-Eaton myasthenic syndrome: immunoglobulin G inhibition of Ca2+ influx in tumor cells correlates with disease severity. Ann Neurol. 1989;25:265–71.PubMedCrossRefGoogle Scholar
  61. 61.
    Meriney SD, Hulsizer SC, Lennon VA, Grinnell AD. Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small cell lung carcinoma. Ann Neurol. 1996;40:739–49.PubMedCrossRefGoogle Scholar
  62. 62.
    Garcia KD, Beam KG. Reduction of calcium currents by Lambert-Eaton syndrome sera: motoneurons are preferentially affected, and L-type currents are spared. J Neurosci. 1996;16:4903–13.PubMedGoogle Scholar
  63. 63.
    Lang B, Newsom-Davis J, Peers C, Prior C, Wray DW. The effect of myasthenic syndrome antibody on presynaptic calcium channels in the mouse. J Physiol. 1987;390:257–70.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med. 1999;340:227–8.PubMedCrossRefGoogle Scholar
  65. 65.
    Giuntoli RL, Lu J, Kobayashi H, Kennedy R, Celis E. Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival and effector function. Clin Cancer Res. 2002;8:922–31.PubMedGoogle Scholar
  66. 66.
    Nakao YK, Motomura M, Fukudome T, Fukuda T, Shiraishi H, Yoshimura T, et al. Seronegative Lambert–Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology. 2002;59:1773–5.PubMedCrossRefGoogle Scholar
  67. 67.
    Oh SJ, Hatanaka Y, Claussen GC, Sher E. Electrophysiological differences in seropositive and seronegative Lambert–Eaton myasthenic syndrome. Muscle Nerve. 2007;35:178–83.PubMedCrossRefGoogle Scholar
  68. 68.
    Hülsbrink R, Hashemolhosseini S. Lambert–Eaton myasthenic syndrome—diagnosis, pathogenesis and therapy. Clin Neurophysiol. 2014;125:2328–36.PubMedCrossRefGoogle Scholar
  69. 69.
    Wirtz PW, Nijnuis MG, Sotodeh M, Willems LNA, Brahim JJ, Putter H, et al. The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. J Neurol. 2003;250:698–701.PubMedCrossRefGoogle Scholar
  70. 70.
    Willcox N, Demaine AG, Newsom-Davis J, Welsh KI, Robb SA, Spiro SG. Increased frequency of IgG heavy chain marker Glm(2) and of HLA-B8 in Lambert-Eaton myasthenic syndrome with and without associated lung carcinoma. Hum Immunol. 1985;14:29–36.PubMedCrossRefGoogle Scholar
  71. 71.
    Parsons KT, Kwok WW, Gaur LK, Nepom GT. Increased frequency of HLA class II alleles DRB1*0301 and DQB1*0201 in Lambert-Eaton myasthenic syndrome without associated cancer. Hum Immunol. 2000;61:828–33.PubMedCrossRefGoogle Scholar
  72. 72.
    Elrington GM, Murray NME, Spiro SG, Newsom-Davis J. Neurological paraneoplastic syndromes in patients with small cell lung cancer: a prospective survey of 150 patients. J Neurol Neurosurg Psychiatry. 1991;54:764–7.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Payne M, Bradbury P, Lang B. Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer. J Thorac Oncol. 2010;5:34–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics 2014. CA Cancer J Clin. 2014;64(1):9–29.PubMedCrossRefGoogle Scholar
  75. 75.
    Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncological profiles of patients seropositive for type 1 anti-neuronal nuclear autoantibodies. Neurology. 1998;50:652–7.PubMedCrossRefGoogle Scholar
  76. 76.
    Yu Z, Kryzer TJ, Griesmann GE, Kim K-K, Benarroch E, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol. 2001;49:146–54.PubMedCrossRefGoogle Scholar
  77. 77.
    Iorio R, Lennon VA. Neural antigen-specific autoimmune disorders. Immunol Rev. 2012;248:104–21.PubMedCrossRefGoogle Scholar
  78. 78.
    Gozzard P, Woodhall M, Chapman C, Nibber A, Waters P, Vincent A, et al. Paraneoplastic neurologic disorders in small cell lung carcinoma. A prospective study. Neurology. 2015;85:235–9.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol. 2004;56:715–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Gutmann L, Phillips LH, Gutmann L. Trends in the association of Lambert-Eaton myasthenic syndrome with carcinoma. Neurology. 1992;42:848–50.PubMedCrossRefGoogle Scholar
  81. 81.
    Argov Z, Shapira Y, Averbuch-Heller L, Wirguin I. Lambert-Eaton myasthenic syndrome (LES) in association with lymphoproliferative disorders. Muscle Nerve. 1995;18:715–9.PubMedCrossRefGoogle Scholar
  82. 82.
    Burns TM, Juel VC, Sanders DB, Phillips LH. Neuroendocrine lung tumors and disorders of the neuromuscular junction. Neurology. 1999;52:1490–1.PubMedCrossRefGoogle Scholar
  83. 83.
    Collins DR, Connolly S, Burns M, Offiah L, Grainger R, Walsh JB. Lambert-Eaton myasthenic syndrome in association with transitional cell carcinoma: a previously unrecognized association. Urology. 1999;54:162.PubMedCrossRefGoogle Scholar
  84. 84.
    Dalmau J, Gultekin HS, Posner JB. Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Brain Pathol. 1999;9:275–84.PubMedCrossRefGoogle Scholar
  85. 85.
    Oyaizu T, Okada Y, Sagawa M, Yamakawa K, Kuroda H, Fujihara K, et al. Lambert-Eaton myasthenic syndrome associated with an anterior mediastinal small cell carcinoma. J Thorac Cardiovasc Surg. 2001;121:1005–6.PubMedCrossRefGoogle Scholar
  86. 86.
    Mckeon A, Apiwattanakul M, Lachance D, Lennon, Mandrekar JN, Boeve BF. Positron emission tomography-computed tomography in paraneoplastic neurologic disorders. Arch Neurol. 2010;67:322–9.PubMedCrossRefGoogle Scholar
  87. 87.
    Kennelly KD, Dodick DW, Pascuzzi RM, Albain KS, Lennon VA. Neuronal autoantibodies and paraneoplastic neurological syndromes associated with extrapulmonary small cell carcinoma. Neurology. 1997;48(Suppl 2):A31.Google Scholar
  88. 88.
    Burns TM, Russell JA, Lachance DH, Jones HR. Oculobulbar involvement is typical with Lambert-Eaton myasthenic syndrome. Ann Neurol. 2003;53:270–3.PubMedCrossRefGoogle Scholar
  89. 89.
    Young JD, Leavitt JA. Lambert-Eaton myasthenic syndrome: ocular signs and symptoms. J Neuroophthalmol. 2016;36:20–2.PubMedCrossRefGoogle Scholar
  90. 90.
    Barr CW, Claussen G, Thomas D, Fesenmeier JT, Pearlman RL, Oh SJ. Primary respiratory failure as the presenting symptom in Lambert-Eaton myasthenic syndrome. Muscle Nerve. 1993;6:712–5.Google Scholar
  91. 91.
    Chan KH, Vernino S, Lennon VA. ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol. 2001;50:301–11.PubMedCrossRefGoogle Scholar
  92. 92.
    Sabater L, Titulaer M, Saiz A, Verschuuren J, Güre AO, Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology. 2008;70:924–8.PubMedCrossRefGoogle Scholar
  93. 93.
    Gadoth A, Kryzer TJ, Fryer J, McKeon A, Lennon VA, Pittock SJ. Microtubule associated protein 1B: novel paraneoplastic biomarker. Ann Neurol. 2017;81:266–77.PubMedCrossRefGoogle Scholar
  94. 94.
    Lee H-R, Lennon VA, Camilleri M, Prather CM. Paraneoplastic gastrointestinal motor dysfunction: clinical and laboratory characteristics. Am J Gastroenterol. 2001;96:373–9.PubMedCrossRefGoogle Scholar
  95. 95.
    Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med. 2000;343:847–55.PubMedCrossRefGoogle Scholar
  96. 96.
    Knowles CH, Lang B, Clover L, Scott SM, Gotti C, Vincent A, Martin JE. A role for autoantibodies in some cases of acquired non-paraneoplastic gut dysmotility. Scand J Gastroenterol. 2002;37:166–70.PubMedCrossRefGoogle Scholar
  97. 97.
    Dhamija R, Tan KM, Pittock SJ, Fox-Orenstein A, Benarroch E, Lennon V. Serologic profiles aiding the diagnosis of autoimmune gastrointestinal dysmotility. Clin Gastroenterol Hepatol. 2008;6:988–92.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Titulaer MJ, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms. Ann N Y Acad Sci. 2008;1132:129–34.PubMedCrossRefGoogle Scholar
  99. 99.
    Gozzard P, Chapman C, Vincent A, Lang B, Maddison P. Novel humoral prognostic markers in small-cell lung carcinoma: a prospective study. PLoS One. 2015;10(11):e0143558.PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Galanis E, Frytak S, Rowland KM, Sloan A, Lennon VA. Neuronal autoantibody titers in the course of small-cell lung carcinoma and platinum-associated neuropathy. Cancer Immunol Immunother. 1999;48:85–90.PubMedCrossRefGoogle Scholar
  101. 101.
    Harms L, Sieb JP, Williams AE, Graham R, Shlaen R, Claus V, et al. Long-term disease history, clinical symptoms, health status, and healthcare utilization in patients suffering from Lambert Eaton myasthenic syndrome: results of a patient interview survey in Germany. J Med Econ. 2012;15:521–30.PubMedCrossRefGoogle Scholar
  102. 102.
    Lundh H, Nilsson O, Rosen I, Johansson S. Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome. Acta Neurol Scand. 1993;88:136–40.PubMedCrossRefGoogle Scholar
  103. 103.
    Sanders DB. 3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LES). Ann N Y Acad Sci. 1998;841:811–6.PubMedCrossRefGoogle Scholar
  104. 104.
    Wirtz PW, Titulaer MJ, Gerven JM, Verschuuren JJ. 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome. Expert Rev Clin Immunol. 2010;6:867–74.PubMedCrossRefGoogle Scholar
  105. 105.
    Oh SJ, Shcherbakova N, Kostera-Pruszczyk A, Alsharabati M, Dimachkie M, Blanco JM, et al. Amifampridine phosphate [Firdapse] is effective and safe in a phase 3 clinical trial in LEMS. Muscle Nerve. 2016;53:717–25.PubMedCrossRefGoogle Scholar
  106. 106.
    Maddison P, McConville J, Farrugia ME, Davies N, Rose M, Norwood F, et al. The use of rituximab in myasthenia gravis and Lambert–Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 2011;82:671–3.PubMedCrossRefGoogle Scholar
  107. 107.
    Small S, Ali HH, Lennon VA, Brown RH, Carr DB, de Armendi A. Anesthesia for unsuspected Lambert-Eaton myasthenic syndrome with autoantibodies and occult small cell lung carcinoma. Anesthesiology. 1992;76:142–5.PubMedCrossRefGoogle Scholar
  108. 108.
    Hatanaka Y, Oh SJ. Ten-second exercise is superior to 30-second exercise for post-exercise facilitation in diagnosing Lambert-Eaton myasthenic syndrome. Muscle Nerve. 2008;37(5):572.PubMedCrossRefGoogle Scholar
  109. 109.
    Oh SJ, Ohira M. Single-fiber EMG and clinical correlation in Lambert-Eaton myasthenic syndrome. Muscle Nerve. 2013;47:664–7.PubMedCrossRefGoogle Scholar
  110. 110.
    Sanders DB, Cao L, Massey JM, Juel VC, Hobson-Webb L, Guptill JT. Is the decremental pattern in Lambert-Eaton syndrome different from that in myasthenia gravis? Clin Neurophysiol. 2014;125:1274–7.PubMedCrossRefGoogle Scholar
  111. 111.
    Oh SJ, Hatanaka Y, Ito E, Nagai T. Post-exercise exhaustion in Lambert–Eaton myasthenic syndrome. Clin Neurophysiol. 2014;125:411–4.PubMedCrossRefGoogle Scholar
  112. 112.
    Chan KH, Lachance DH, Harper CM, Lennon VA. Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle Nerve. 2007;36:651–8.PubMedCrossRefGoogle Scholar
  113. 113.
    Titulaer MJ, Maddison P, Sont JK, Wirtz PW, Hilton-Jones D, Klooster R, et al. Clinical Dutch-English Lambert-Eaton myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol. 2011;29:902–8.PubMedCrossRefGoogle Scholar
  114. 114.
    Vernino S, Adamski J, Kryzer TJ, Lennon VA. Neuronal nicotinic AChR antibody in subacute autonomic neuropathy and cancer-related syndromes. Neurology. 1998;50:1806–13.PubMedCrossRefGoogle Scholar
  115. 115.
    Lennon VA, Kryzer TJ. Correspondence: neuronal calcium channel autoantibodies coexisting with type 1 Purkinje cell cytoplasmic autoantibodies (PCA-1 or “anti-Yo”). Neurology. 1998;51:327–8.PubMedCrossRefGoogle Scholar
  116. 116.
    Albers JW, Faulkner JA, Dorovini-Zis K. Abnormal neuromuscular transmission in an infantile myasthenic syndrome. Ann Neurol. 1984;16:28–34.PubMedCrossRefGoogle Scholar
  117. 117.
    Bady B, Chauplannaz G, Carrier H. Congenital Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 1987;50:476–8.PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
    Katz JS, Wolfe GI, Bryan WW, Tintner R, Barohn RJ. Acetylcholine receptor antibodies in the Lambert-Eaton myasthenic syndrome. Neurology. 1998;50:470–5.PubMedCrossRefGoogle Scholar
  119. 119.
    Kamenskaya MA, Elmqvist D, Thesleff S. Guanidine and neuromuscular transmission. IL effect on transmitter release in response to repetitive nerve stimulation. Arch Neurol. 1975;32:510–8.PubMedCrossRefGoogle Scholar
  120. 120.
    Cherington M. Guanidine and germine in Eaton-Lambert syndrome. Neurology. 1976;26:944–6.PubMedCrossRefGoogle Scholar
  121. 121.
    Blumhardt LD, Joekes AM, Marshall J, Philalithis PE. Guanidine treatment and impaired renal function in the Eaton-Lambert syndrome. Br Med J. 1977;1:946–7.PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Silbert PL, Hankey GJ, Barr AL. Successful alternate day guanidine therapy following guanidine-induced neutropenia in the Lambert-Eaton myasthenic syndrome. Muscle Nerve. 1990;13:360–1.PubMedCrossRefGoogle Scholar
  123. 123.
    Harper CM, McEvoy KM, Windebank AJ, Daube JR. Effect of 3,4-diaminopyridine on neuromuscular transmission in patients with Lambert-Eaton myasthenic syndrome. Electroencephalogr Clin Neurophysiol. 1990;75:557.CrossRefGoogle Scholar
  124. 124.
    Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology. 2000;54:603–7.PubMedCrossRefGoogle Scholar
  125. 125.
    Oh SJ, Claussen G, Hatanaka Y, Morgan MB. 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle Nerve. 2009;40:795–800.PubMedCrossRefGoogle Scholar
  126. 126.
    Wirtz PW, Verschuuren JJ, van Dijk JG, de Kam ML, Schoemaker RC, van Hasselt JG, et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther. 2009;86:44–8.PubMedCrossRefGoogle Scholar
  127. 127.
    Wu ZZ, Li DP, Chen SR, Pan HL. Aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-activated calcium channel beta subunit. J Biol Chem. 2009;284:36453–61.PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Kim DS, Claussen GC, Oh SJ. Single-fiber electromyography improvement with 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Muscle Nerve. 1998;21(8):1107.PubMedCrossRefGoogle Scholar
  129. 129.
    Flet L, Polard E, Guillard O, Leray E, Allain H, Loic J, et al. 3,4-Diaminopyridine safety in clinical practice: an observational, retrospective cohort study. J Neurol. 2010;257:937–46.PubMedCrossRefGoogle Scholar
  130. 130.
    Boerma CE, Rommes JH, van Leeuwen RB, Bakker J. Cardiac arrest following an iatrogenic 3,4-diaminopyridine intoxication in a patient with Lambert-Eaton myasthenic syndrome. Clin Toxicol. 1995;33:249–51.Google Scholar
  131. 131.
    Tarr TB, Malick W, Liang M, Valdomir G, Frasso M, Lacomis D, et al. Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndrome. J Neurosci. 2013;33:10559–67.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Tarr TB, Lacomis D, Reddel SW, Liang M, Valdomir G, Frasso M, et al. Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist. J Physiol. 2014;592:3687–96.PubMedPubMedCentralCrossRefGoogle Scholar
  133. 133.
    Dau PC, Denys EH. Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome. Ann Neurol. 1982;11:570–5.PubMedCrossRefGoogle Scholar
  134. 134.
    Bird SJ. Clinical and electrophysiologic improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy. Neurology. 1992;42:1422–3.PubMedCrossRefGoogle Scholar
  135. 135.
    Motomura M, Tsujihata M, Takeo G, Matsuo H, Kinoshita I, Nakamura T, et al. The effect of high-dose gamma-globulin in Lambert-Eaton myasthenic syndrome. Neurol Ther. 1994;11:377–83.Google Scholar
  136. 136.
    Takano H, Tanaka M, Koike R, Nagai H, Arakawa M, Tsuji S. Effect of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome with small-cell lung cancer: correlation with the titer of anti-voltage-gated calcium channel antibody. Muscle Nerve. 1994;17:1074–5.CrossRefGoogle Scholar
  137. 137.
    Pellkofer HL, Voltz R, Kuempfel T. Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction. Muscle Nerve. 2009;40:305–8.PubMedCrossRefGoogle Scholar
  138. 138.
    Bain PG, Motomura M, Newsom-Davis J, Misbah SA, Chapel HM, Lee ML, et al. Effects of intravenous immunoglobulin (IVIg) treatment on muscle weakness and calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology. 1996;47:678–83.PubMedCrossRefGoogle Scholar
  139. 139.
    Weiss N, Zamponi GW. Trafficking of neuronal calcium channels. Neuronal Signal. 2017;1.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Clinical Neurophysiology and Neuromuscular Disease, Department of NeurologyMayo ClinicRochesterUSA
  2. 2.Departments of Neurology and Laboratory Medicine and Pathology, Divisions of Clinical Neurophysiology and Neuromuscular Disease, and Neuroimmunology LaboratoryMayo ClinicRochesterUSA

Personalised recommendations